Abbisko Cayman Limited (HK:2256) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Abbisko Cayman Limited’s subsidiary, Abbisko Therapeutics, is set to present promising phase 2 study results of its drug pimicotinib at the upcoming American Society of Hematology Annual Conference. The study focuses on pimicotinib’s potential in treating chronic graft-versus-host disease in patients unresponsive to previous treatments. Investors are advised to stay informed as the company explores new therapeutic avenues.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.